A 42-year-old man from rural Maharashtra presents with a 3-week history of progressive muscle weakness, tremors, and excessive salivation. He works as a pesticide sprayer and was exposed to organophosphate compounds 2 weeks ago without proper protective equipment. On examination, he has pinpoint pupils, bradycardia (HR 48/min), and visible muscle fasciculations. Serum cholinesterase levels are markedly reduced to 20% of normal. Which type of enzyme inhibition best describes the mechanism of organophosphate toxicity?

Explanation

## Organophosphate Poisoning and Enzyme Inhibition Mechanism ### Pathophysiology of Organophosphate Toxicity **Key Point:** Organophosphates cause irreversible inhibition of acetylcholinesterase (AChE) by phosphorylating the serine residue (Ser203) in the active site, permanently inactivating the enzyme. ### Mechanism of Irreversible Inhibition 1. Organophosphates form a covalent phosphoester bond with the hydroxyl group of serine in AChE's catalytic triad 2. Unlike reversible inhibitors, this bond does NOT hydrolyze spontaneously 3. The enzyme remains permanently disabled until new AChE is synthesized (takes days to weeks) 4. Acetylcholine accumulates in synapses → cholinergic crisis ### Clinical Manifestations Linked to AChE Inhibition | Feature | Mechanism | |---------|----------| | Pinpoint pupils (miosis) | Unopposed parasympathetic stimulation of ciliary muscle | | Excessive salivation & bronchospasm | Muscarinic effects from ACh accumulation | | Muscle fasciculations & weakness | Nicotinic effects; depolarization block at neuromuscular junction | | Bradycardia | Vagal stimulation from ACh excess | | Reduced serum cholinesterase | Irreversible phosphorylation of enzyme | ### Why This Is Irreversible (Not Reversible) **High-Yield:** The critical difference: - **Reversible inhibitors** (e.g., physostigmine, neostigmine) form a carbamylated intermediate that hydrolyzes in minutes to hours - **Irreversible inhibitors** (organophosphates, nerve agents) form a phosphoester bond that is extremely stable; hydrolysis does NOT occur spontaneously **Clinical Pearl:** Once "aging" occurs (loss of an alkyl group from the phosphoester), the inhibition becomes truly irreversible even to oximes like pralidoxime (2-PAM). Early treatment within hours is critical. ### Treatment Rationale - **Atropine:** Blocks muscarinic receptors (symptomatic relief) - **Pralidoxime (2-PAM):** Reactivates AChE by removing the phosphate group (only effective before aging) - **Supportive care:** Airway management, mechanical ventilation if needed ```mermaid flowchart TD A[Organophosphate exposure]:::outcome --> B[Enters nervous system] B --> C[Binds to AChE serine residue]:::action C --> D{Phosphoester bond formed}:::decision D -->|Immediately| E[Irreversible inhibition]:::urgent E --> F[ACh accumulation in synapse]:::outcome F --> G[Cholinergic crisis]:::urgent G --> H1[Muscarinic: miosis, salivation, bradycardia]:::outcome G --> H2[Nicotinic: fasciculations, weakness]:::outcome E --> I{Time since exposure}:::decision I -->|< 24-48 hrs| J[2-PAM can reactivate AChE]:::action I -->|> 48 hrs| K[Aging occurred - irreversible]:::urgent ``` ### Distinction from Other Inhibition Types ~~Reversible competitive~~ — substrate concentration cannot overcome phosphorylation; the inhibitor is covalently bound ~~Allosteric~~ — organophosphates bind directly to the active site, not a regulatory site ~~Uncompetitive~~ — these bind only to ES complex; organophosphates bind to free enzyme [cite:Lehninger Principles of Biochemistry Ch 6]